Nature Reviews: Drug Discovery 2011-10-01

Ezogabine (retigabine).

Carl E Stafstrom, Seden Grippon, Peter Kirkpatrick

Index: Nat. Rev. Drug Discov. 10(10) , 729-30, (2011)

Full Text: HTML

Abstract

Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the U.S. Food and Drug Administration (F.D.A.) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).

Related Compounds

  • Retigabine

Related Articles:

Enhanced in vitro CA1 network activity in a sodium channel β1(C121W) subunit model of genetic epilepsy.

2014-04-01

[Epilepsia 55(4) , 601-8, (2014)]

Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel.

2013-11-01

[Expert Opin. Drug Saf. 12(6) , 847-55, (2013)]

Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review.

2012-09-01

[Clin. Ther. 34(9) , 1845-56.e1, (2012)]

[Retigabine - a new antiepileptic drug with a different mechanism of action].

2013-01-01

[Postepy. Hig. Med. Dosw. 67 , 973-81, (2013)]

P-retigabine: an N-propargyled retigabine with improved brain distribution and enhanced antiepileptic activity.

2015-01-01

[Mol. Pharmacol. 87(1) , 31-8, (2015)]

More Articles...